MLTX
NASDAQ · Biotechnology
Moonlake Immunotherapeutics
$12.38
-0.01 (-0.08%)
Open$12.41
Previous Close$12.39
Day High$12.51
Day Low$12.24
52W High$62.75
52W Low$5.95
Volume—
Avg Volume1.81M
Market Cap1.05B
P/E Ratio—
EPS$-3.83
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-14.9% upside
Current
$12.38
$12.38
Target
$10.54
$10.54
$8.06
$10.54 avg
$16.98
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 207.37M | 195.61M | 178.47M |
| Net Income | -41,056,867 | -38,376,149 | -44,335,912 |
| Profit Margin | -19.8% | -19.6% | -24.8% |
| EBITDA | -81,449,014 | -69,654,675 | -60,804,840 |
| Free Cash Flow | -45,845,658 | -33,391,408 | -32,934,200 |
| Rev Growth | +19.2% | +9.7% | +1.7% |
| Debt/Equity | 0.11 | 0.10 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |